ISIN | LU1587985141 |
---|---|
Valorennummer | |
Bloomberg Global ID | |
Fondsname | Bellevue Asia Pacific Healthcare B CHF |
Fondsanbieter |
Bellevue Asset Management AG
Zürich, Schweiz Telefon: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fondsanbieter | Bellevue Asset Management AG |
Vertreter in der Schweiz |
Waystone Fund Services (Switzerland) SA Lausanne Telefon: 0041213111781 |
Distributor(en) |
Bank am Bellevue AG Küsnacht Telefon: +41 44 267 67 67 |
Anlagekategorie | Aktienfonds |
EFC-Kategorie | |
Anteilskategorie | Accumulation |
Domizilland | Luxemburg |
Konditionen bei der Ausgabe | Kombination von Ausgabekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
Konditionen bei der Rücknahme | Kombination von Rücknahmekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
Investment-Strategie *** | The sub-fund is an equity fund. The investment objective of the sub-fund is to achieve long-term capital growth by investing at least two thirds of the net assets of the fund in a portfolio of carefully chosen shares and other equity securities of companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of the Asia-Pacific region. The universe for companies is determined cumulatively as follows: Shares of companies that have their registered office or carry out the majority of their economic activity in the healthcare sector in the Asia-Pacific region. These include companies operating in such areas as generics, medtech, biotech, pharma and health services which are involved in the development, manufacture or sale of products and services. Listed on a recognised stock market or, in the case of an initial public offering, the company has applied for listing on the relevant exchange. |
Besonderheiten |
Aktueller Preis * | 140.09 CHF | 03.10.2024 |
---|---|---|
Vorheriger Preis * | 139.82 CHF | 02.10.2024 |
52 Wochen Hoch * | 140.92 CHF | 12.10.2023 |
52 Wochen Tief * | 124.46 CHF | 05.08.2024 |
NAV * | 140.09 CHF | 03.10.2024 |
Ausgabepreis * | ||
Rücknahmepreis * | ||
Schlusskurs * | ||
Indikativer Minimalpreis | ||
Fondsvermögen *** | 122'381'577 | |
Anteilsklassevermögen *** | ||
Trading Information SIX |
YTD-Performance | +6.05% |
29.12.2023 - 03.10.2024
29.12.2023 03.10.2024 |
---|---|---|
1 Monat | +1.17% |
03.09.2024 - 03.10.2024
03.09.2024 03.10.2024 |
3 Monate | +7.88% |
03.07.2024 - 03.10.2024
03.07.2024 03.10.2024 |
6 Monate | +4.94% |
03.04.2024 - 03.10.2024
03.04.2024 03.10.2024 |
1 Jahr | +0.87% |
03.10.2023 - 03.10.2024
03.10.2023 03.10.2024 |
2 Jahre | -7.98% |
03.10.2022 - 03.10.2024
03.10.2022 03.10.2024 |
3 Jahre | -40.32% |
04.10.2021 - 03.10.2024
04.10.2021 03.10.2024 |
5 Jahre | -43.86% |
15.06.2021 - 03.10.2024
15.06.2021 03.10.2024 |
Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Daiichi Sankyo Co Ltd | 9.44% | |
---|---|---|
Otsuka Holdings Co Ltd | 5.85% | |
CSL Ltd | 5.71% | |
Samsung BioLogics Co Ltd | 5.54% | |
Legend Biotech Corp ADR | 5.19% | |
Takeda Pharmaceutical Co Ltd | 4.49% | |
Olympus Corp | 4.39% | |
Celltrion Inc | 4.13% | |
Innovent Biologics Inc | 3.75% | |
BeiGene Ltd ADR | 3.69% | |
Letzte Daten-Aktualisierung | 31.08.2024 |
TER | 2.27% |
---|---|
Datum TER | 29.01.2021 |
Performance Fee *** | 10.00% |
PTR | |
Max. Management Fee *** | 1.60% |
Ongoing Charges *** | 2.20% |
SRRI ***
|
|
Datum SRRI *** | 30.09.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |